search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.


- candidate number25490
- NTR NumberNTR6119
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR1-nov-2016
- Secondary IDsESR-16-11856 Astra Zeneca
- Public TitleSingle low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
- Scientific Title‘DURVIT’: Single low-dose DURValumab IntraTumorally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
- ACRONYMDURVIT
- hypothesisThe current systemic treatment with PD-1 and PD-L1 inhibitors can cause autoimmune side effects. As cervical cancer does not readily metastasize to distant organs but initially to regional lymph nodes we believe that local administration of PD-1/PD-L1 checkpoint inhibitors at an early stage will deliver these antibodies exactly where they are needed resulting in a major clinical benefit for these patients while reducing undesirable systemic side effect: this is the central hypothesis of our study. Additional interest in local administration of checkpoint inhibitors is raised by the fact that the locally administered doses are expected to be much lower, leading to a critical and highly desirable decline in the expenses involved, which threaten to cripple the health care system.
For this Phase-I study, we hypothesize that it is safe to locally administer durvalumab in patients with cervical cancer, scheduled to undergo surgery (lymphadenectomy or lymph node debulking in the context of radical hysterectomy or chemoradiation, respectively). The primary endpoint of this study is safety on the basis of assessment of AEs and serious AEs. This will be measured according to the standard procedures. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 will be used for this.
- Healt Condition(s) or Problem(s) studiedCervix cancer, Immune therapy
- Inclusion criteria • Age > 18 years at time of study entry
• Willing and able to undergo the planned study procedures
• World Health Organisation (WHO) performance status of 0 or 1
• Written informed consent
• Histologically confirmed cervical cancer of al histological types
• Scheduled to undergo lymphadenectomy or lymph node debulking in context of radical hysterectomy or chemo-radiation respectively
• No indication of an active infectious disease: HIV, HCV and HBV negative
• No history of autoimmune disease or systematic underlying disease which might affect immunocompetence
• Adequate bone marrow function
• Subjects must either be of non-reproductive potential or must have a negative urine pregnancy test upon study entry
• Ability of subject to understand Dutch language
- Exclusion criteria• Prior treatment with a PD1 or PD-L1 inhibitor, including durvalumab
• Involvement in the planning and/or conduct of the study
• Participation in a study with another investigational drug within 30 days prior to enrolment in this study
• Severe cardiac, respiratory, or metabolic disease
• Use of oral anticoagulant drugs (except ascal)
• Severe infections requiring antibiotics
• Lactation or pregnancy
• Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
• Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
• Active or prior documented autoimmune disease within the past 2 years
• Active or prior documented inflammatory bowel disease
• History of primary immunodeficiency/allogeneic organ transplant/previous clinical diagnosis of tuberculosis/ uncontrolled intercurrent illness
• Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
• Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- mec approval receivedno
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-apr-2016
- planned closingdate1-apr-2018
- Target number of participants12
- InterventionsThis is a non-randomized, single-arm, open-label, phase I study. Patients with cervical cancer who are scheduled for lymph node dissection or lymph node debulking in the context of a radical hysterectomy or chemo-radiation will be enrolled at the AMC. Two weeks before the scheduled surgical treatment of the patients, durvalumab will be injected locally into the cervix. Three doses of durvalumab will be tested in a 3+3 dose escalation design: 5, 10 and 20 mg. The Common Terminology Criteria for Adverse Events (CTCAE) v4.3 will be used for the assessment of adverse events. The injection procedure is identical to the i.t. injections already performed in a standardized fashion for the sentinel lymph node procedure in various centers. Blood samples will be taken once during the screening period, at day 0 (prior to durvalumab administration, i.e. baseline), at day +14 (at the time of surgery), after 4 weeks, and at 3 months after administration of durvalumab.
During surgery, patent blue will be injected intratumorally (in the same manner as the durvalumab injection), for identification of the sentinel lymph nodes.
Post-surgery biopsies of the removed tumour and draining lymph node samples as well as pre- and posttreatment peripheral blood samples will be collected for immunomonitoring.
The proposed correlative immunoassays will shed light on mechanisms underlying the biological effects of PD-L1 blockade and may demonstrate its biological efficacy, they will aid in the selection of optimal dose and target population for subsequent studies, and facilitate a rational approach to the design of subsequent Phase II trials of this novel immunotherapy.
- Primary outcomeThis is a phase-I study and therefore we have the following primary objective: to study clinical safety and tolerability a of locally administered single dose of durvalumab in cervical cancer patients scheduled to undergo lymphadenectomy or lymph node debulking in the context of radical hysterectomy or chemo radiation. This method of administration has not been tested before in cervical cancer patients. We expect the occurrence and severity of AEs to be much lower as compared to intravenous administration of durvalumab. Safety will be evaluated through the analysis of Adverse Events (AE), laboratory tests, physical examination, vital signs and performance status. The Common Terminology Criteria for Adverse Events (CTCAE) v4.03 will be used for the assessment of adverse events. The primary goal of the study is to determine the maximum tolerated dose (MTD) of local injection of durvalumab in cervical cancer patients.
- Secondary outcomeThe secondary objective is to study the immunological effects of locally administered durvalumab on the microenvironment of the primary tumour and the draining lymph nodes as well as on the systemic antitumor immune response. As previously stated, we have already studied the immune status of cervical tumours and their draining lymph nodes and will now study the effect of durvalumab and ascertain its possible ability to affect PD-L1 expression in macrophages and Treg rates.
- TimepointsPrimary outcome: The Common Terminology Criteria for Adverse Events (CTCAE) v4.03 will be used for the assessment of adverse events at timepoints: day 0 (injection durvalumab), day 14 (surgery), week 4 and month 3.

Secondary outcome:
* To characterize the primary tumour microenvironment in pre- and post-treatment biopsies of tumours and lymph nodes of the patients included in the dose escalation study by seven colour fluorescent immunohistochemistry.
• To analyze viable tumour- and lymph node material (single-cell suspensions) as well as peripheral blood by 8-10 multi-colour FACS panels and exploratory CYTOF analyses, before and after anti-PD-L1 treatment.
• Frequencies of HPV-specific T cells (HPV-16 E6/E7) will be assessed by IFNγ elispot assay using established in vitro stimulation culture protocols and by ultra-sensitive MHC-I tetramer analysis.
• Functional Th1/2/17 activity will be monitored by ex vivo polyclonal stimulation.
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESdrs. Jossie Rotman
- CONTACT for SCIENTIFIC QUERIESdrs. Jossie Rotman
- Sponsor/Initiator VUmc-CCA (Cancer Center Amsterdam)
- Funding
(Source(s) of Monetary or Material Support)
CCA fonds, Astra Zeneca
- Publications
- Brief summary This is a non-randomized, single-arm, open-label, phase I study. Patients with cervical cancer who are scheduled for lymph node dissection or lymph node debulking in the context of a radical hysterectomy or chemo-radiation will be enrolled at the AMC.
Two weeks before the scheduled surgical treatment of the patients, durvalumab will be injected locally into the cervix. Three doses of durvalumab will be tested in a 3+3 dose escalation design: 5, 10 and 20 mg. The Common Terminology Criteria for Adverse Events (CTCAE) v4.3 will be used for the assessment of adverse events. The injection procedure is identical to the i.t. injections already performed in a standardized fashion for the sentinel lymph node procedure in various centers. Blood samples will be taken once during the screening period, at day 0 (prior to durvalumab administration, i.e. baseline), at day +14 (at the time of surgery), after 4 weeks, and at 3 months after administration of durvalumab.
During surgery, patent blue will be injected intratumorally (in the same manner as the durvalumab injection), for identification of the sentinel lymph nodes.
Post-surgery biopsies of the removed tumour and draining lymph node samples as well as pre- and posttreatment peripheral blood samples will be collected for immunomonitoring. The proposed correlative immunoassays will shed light on mechanisms underlying the biological effects of PD-L1 blockade and may demonstrate its biological efficacy, they will aid in the selection of optimal dose and target population for subsequent studies, and facilitate a rational approach to the design of subsequent Phase II trials of this novel immunotherapy.
- Main changes (audit trail)
- RECORD1-nov-2016 - 11-dec-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl